202 related articles for article (PubMed ID: 24094436)
1. Synthesis and biological evaluation of 5-carbamoyl-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors.
Goto T; Shiina A; Yoshino T; Mizukami K; Hirahara K; Suzuki O; Sogawa Y; Takahashi T; Mikkaichi T; Nakao N; Takahashi M; Hasegawa M; Sasaki S
Bioorg Med Chem; 2013 Nov; 21(22):7025-37. PubMed ID: 24094436
[TBL] [Abstract][Full Text] [Related]
2. Identification of the fused bicyclic 4-amino-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors.
Goto T; Shiina A; Yoshino T; Mizukami K; Hirahara K; Suzuki O; Sogawa Y; Takahashi T; Mikkaichi T; Nakao N; Takahashi M; Hasegawa M; Sasaki S
Bioorg Med Chem Lett; 2013 Jun; 23(11):3325-8. PubMed ID: 23602400
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological activity of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel and potent phosphodiesterase type 4 inhibitors.
Taltavull J; Serrat J; Gràcia J; Gavaldà A; Córdoba M; Calama E; Montero JL; Andrés M; Miralpeix M; Vilella D; Hernández B; Beleta J; Ryder H; Pagès L
Eur J Med Chem; 2011 Oct; 46(10):4946-56. PubMed ID: 21871695
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of nimesulide based new class of triazole derivatives as potential PDE4B inhibitors against cancer cells.
Mareddy J; Nallapati SB; Anireddy J; Devi YP; Mangamoori LN; Kapavarapu R; Pal S
Bioorg Med Chem Lett; 2013 Dec; 23(24):6721-7. PubMed ID: 24215890
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological evaluation of novel catecholopyrimidine based PDE4 inhibitor for the treatment of atopic dermatitis.
Purushothaman B; Arumugam P; Kulsi G; Song JM
Eur J Med Chem; 2018 Feb; 145():673-690. PubMed ID: 29353721
[TBL] [Abstract][Full Text] [Related]
6. Action of a Novel PDE4 inhibitor ZL-n-91 on lipopolysaccharide-induced acute lung injury.
Tang HF; Lu JJ; Tang JF; Zheng X; Liang YQ; Wang XF; Wang YJ; Mao LG; Chen JQ
Int Immunopharmacol; 2010 Apr; 10(4):406-11. PubMed ID: 20074667
[TBL] [Abstract][Full Text] [Related]
7. Discovery of oxazole-based PDE4 inhibitors with picomolar potency.
Kuang R; Shue HJ; Xiao L; Blythin DJ; Shih NY; Chen X; Gu D; Schwerdt J; Lin L; Ting PC; Cao J; Aslanian R; Piwinski JJ; Prelusky D; Wu P; Zhang J; Zhang X; Celly CS; Billah M; Wang P
Bioorg Med Chem Lett; 2012 Apr; 22(7):2594-7. PubMed ID: 22401864
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of a pyrido[2,3-d]pyrimidin-5-one class of anti-inflammatory FMS inhibitors.
Huang H; Hutta DA; Hu H; DesJarlais RL; Schubert C; Petrounia IP; Chaikin MA; Manthey CL; Player MR
Bioorg Med Chem Lett; 2008 Apr; 18(7):2355-61. PubMed ID: 18342505
[TBL] [Abstract][Full Text] [Related]
9. Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration.
Woodrow MD; Ballantine SP; Barker MD; Clarke BJ; Dawson J; Dean TW; Delves CJ; Evans B; Gough SL; Guntrip SB; Holman S; Holmes DS; Kranz M; Lindvaal MK; Lucas FS; Neu M; Ranshaw LE; Solanke YE; Somers DO; Ward P; Wiseman JO
Bioorg Med Chem Lett; 2009 Sep; 19(17):5261-5. PubMed ID: 19656678
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluation of novel quinazoline-based anti-inflammatory agents acting as PDE4B inhibitors.
Serya RA; Abbas AH; Ismail NS; Esmat A; Abou El Ella DA
Chem Pharm Bull (Tokyo); 2015; 63(2):102-16. PubMed ID: 25748781
[TBL] [Abstract][Full Text] [Related]
11. Identification of 2,3-disubstituted pyridines as potent, orally active PDE4 inhibitors.
Kato Y; Kawasaki M; Nigo T; Nakamura S; Fusano A; Teranishi Y; Ito MN; Sumiyoshi T
Bioorg Med Chem; 2013 Sep; 21(18):5851-4. PubMed ID: 23910988
[TBL] [Abstract][Full Text] [Related]
12. Novel thieno[2,3-d]pyrimidines: their design, synthesis, crystal structure analysis and pharmacological evaluation.
Adepu R; Rambabu D; Prasad B; Meda CL; Kandale A; Krishna GR; Reddy CM; Chennuru LN; Parsa KV; Pal M
Org Biomol Chem; 2012 Aug; 10(29):5554-69. PubMed ID: 22710638
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluation of tetrahydroisoquinolines derivatives as novel, selective PDE4 inhibitors for antipsoriasis treatment.
Zhang R; Li H; Zhang X; Li J; Su H; Lu Q; Dong G; Dou H; Fan C; Gu Z; Mu Q; Tang W; Xu Y; Liu H
Eur J Med Chem; 2021 Feb; 211():113004. PubMed ID: 33218684
[TBL] [Abstract][Full Text] [Related]
14. Rational design of conformationally constrained oxazolidinone-fused 1,2,3,4-tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.
Song G; Zhu X; Li J; Hu D; Zhao D; Liao Y; Lin J; Zhang LH; Cui ZN
Bioorg Med Chem; 2017 Oct; 25(20):5709-5717. PubMed ID: 28888661
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of 2,2,4-trimethyl-1,2-dihydroquinolinyl substituted 1,2,3-triazole derivatives: their evaluation as potential PDE 4B inhibitors possessing cytotoxic properties against cancer cells.
Praveena KS; Durgadas S; Suresh Babu N; Akkenapally S; Ganesh Kumar C; Deora GS; Murthy NY; Mukkanti K; Pal S
Bioorg Chem; 2014 Apr; 53():8-14. PubMed ID: 24463218
[TBL] [Abstract][Full Text] [Related]
16. Construction of a six-membered fused N-heterocyclic ring via a new 3-component reaction: synthesis of (pyrazolo)pyrimidines/pyridines.
Kumar PM; Kumar KS; Mohakhud PK; Mukkanti K; Kapavarapu R; Parsa KV; Pal M
Chem Commun (Camb); 2012 Jan; 48(3):431-3. PubMed ID: 22075973
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and bioactivity of pyrazole and triazole derivatives as potential PDE4 inhibitors.
Li YS; Tian H; Zhao DS; Hu DK; Liu XY; Jin HW; Song GP; Cui ZN
Bioorg Med Chem Lett; 2016 Aug; 26(15):3632-5. PubMed ID: 27289320
[TBL] [Abstract][Full Text] [Related]
18. Effects of the new benzimidazole derivative TAS-203, an orally active phosphodiesterase 4 inhibitor, on airway inflammation in rats and emetic responses in ferrets.
Asaka N; Kakuo H; Ohmori K; Sasaki E; Togawa M; Yamada S; Oka T; Kiniwa M
Arzneimittelforschung; 2010; 60(9):564-70. PubMed ID: 21117500
[TBL] [Abstract][Full Text] [Related]
19. Anti-neutrophilic inflammatory activity of ASP3258, a novel phosphodiesterase type 4 inhibitor.
Kubo S; Kobayashi M; Iwata M; Miyata K; Takahashi K; Shimizu Y
Int Immunopharmacol; 2012 Jan; 12(1):59-63. PubMed ID: 22041526
[TBL] [Abstract][Full Text] [Related]
20. Thiophene inhibitors of PDE4: crystal structures show a second binding mode at the catalytic domain of PDE4D2.
Nankervis JL; Feil SC; Hancock NC; Zheng Z; Ng HL; Morton CJ; Holien JK; Ho PW; Frazzetto MM; Jennings IG; Manallack DT; Martin TJ; Thompson PE; Parker MW
Bioorg Med Chem Lett; 2011 Dec; 21(23):7089-93. PubMed ID: 22030030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
